INGAP Peptide

DRUG2 trials

Sponsors

GMP Endotherapeutics, Exsulin Corporation

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Type 1 Diabetes Mellitus

Phase 1

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

CompletedNCT00034255

GMP EndotherapeuticsDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Start: 2001-12-31Target: 62Updated: 2005-06-24

Phase 2

Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults

TerminatedNCT00995540

Exsulin CorporationType 1 Diabetes Mellitus

Start: 2009-11-30End: 2011-12-31Updated: 2014-02-12